European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunization Documentation 98

STAT

MAY 19, 2023

Now, 20 years later, we have a cure for hepatitis C and a highly effective vaccine and treatment for hepatitis B — but annual deaths from the two are projected to outnumber deaths from HIV, tuberculosis, and malaria combined by 2040. Viral hepatitis affects almost 400 million people and kills more than 1 million each year.

Vaccines 104

Vaccines 104

European Pharmaceutical Review

JULY 12, 2023

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Vaccines 137

Vaccines Hospitals 137

Fierce Pharma

OCTOBER 31, 2024

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.

Vaccines 105

Vaccines 105

STAT

SEPTEMBER 29, 2022

The Covid-19 pandemic set back many of the global health goals for 2030. One of the most feasible to recover is the target of eliminating human deaths from rabies , thanks to an effective, inexpensive vaccine for dogs.

Vaccines 120

Vaccines 120

STAT

FEBRUARY 12, 2024

Novo Holdings, the controlling shareholder of Novo Nordisk, plans to invest about $35 billion by 2030 , Reuters writes. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030.

Vaccines 116

Vaccines Communication Hospitals 116

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunization 78

STAT

JANUARY 12, 2023

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.

Vaccines 104

Vaccines 104

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies Vaccines 104

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 65

Vaccines Immunization 65

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunization 111

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. BioNTech to support trial access for cancer immunotherapies Developing an mRNA cancer vaccine In terms of disease indication, melanoma remains the primary focus of advanced mRNA-based therapies, GlobalData reported.

Immunization 110

Immunization Vaccines 110

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. If successfully developed, this means cancer vaccines could become part of standard care. Signing of this agreement builds on a memorandum of understanding signed in January.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Immunization 116

Immunization Vaccines 116

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunization Hospitals Packaging 145

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 New types of drugs, such as oral vaccines, will also be formulated as capsules. Insights on the Empty Capsules Global Market to 2030 – Featuring ACG Worldwide, Bright Pharma Caps and Lonza Among Others [Internet]. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines 124

Pharmaceutical Technology

JUNE 27, 2022

The international agency had previously set a target of eliminating viral hepatitis by 2030. As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion.

Vaccines 105

Vaccines 105

pharmaphorum

MAY 11, 2022

If approved, nirsevimab would provide a new option for managing RSV, ahead of the possible rollout of vaccines that could be used to protect young children. Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year.

Vaccines 64

Vaccines FDA 64

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

pharmaphorum

JANUARY 15, 2021

Now, speaking to him as the first vaccines are deployed in the UK, he highlights the importance of GSK’s employees and culture to the future of the company post-COVID. With the new goals, GSK aims to have a net zero impact on climate and a net positive impact on nature by 2030.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.

Vaccines 52

Vaccines 52

pharmaphorum

AUGUST 4, 2022

Thousands of people in the UK will be screened for hepatitis C virus in a new pilot aimed at expanding use of antiviral therapies to eradicate the infectious – and eliminate it altogether by 2030.

Vaccines 52

Vaccines Hospitals 52

pharmaphorum

JANUARY 24, 2023

Where medicines are biologics, such as vaccines, insulin, blood products, and numerous specialty medicines, failsafe cold chains will be necessary from manufacturer to patient. Wholesalers and pharmacies operate under regulations which define storage, supply, and service standards, and these come with energy requirements.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

PharmaShots

APRIL 11, 2023

Bleeding after circumcision Bleeding after having shots, such as vaccinations. by 2030 at a CAGR of 6.9% Symptoms:1 Prolonged oozing after injuries, tooth extractions or surgery Hematoma Bruising Bleeding into the joints, mouth and gums Bleeding of the mouth and gums, and bleeding that is hard to stop after losing a tooth.

Immunization 64

Immunization Vaccines 64

Pharmaceutical Technology

JUNE 30, 2022

By 2030, it strives to “free more than one billion people who currently require interventions against neglected tropical diseases.”. In Muratov’s opinion, this was reflective of a wider pattern seen in almost any other field of research, which could now change with the development of Covid-19 vaccines and antivirals.

Vaccines 64

Vaccines FDA Hospitals 64

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Pfizer’s RSVpreF vaccine is in hot pursuit of GSK’s shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults.

Vaccines 102

Vaccines 102

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.

Vaccines 110

Vaccines Communication Documentation Compounding 110

pharmaphorum

SEPTEMBER 8, 2022

On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The post FDA gives Pfizer’s Group B strep vaccine breakthrough status appeared first on.

Vaccines 52

Vaccines FDA 52

Pharmaceutical Technology

MARCH 31, 2023

The company will construct the new advanced mRNA facility, which is claimed to be Moderna’s first mRNA manufacturing facility in Africa and is expected to have the capacity to produce up to 500 million vaccine doses annually. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 105

Vaccines 105

pharmaphorum

JUNE 22, 2022

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. Construction of the facility is expected to start later this year, said the government, with the first mRNA vaccines due to be produced there in 2025.

Vaccines 59

Vaccines 59